SecBot SecBot
PRESS-RELEASE ·Filed Nov 10, 2026

FRNM

Freenome, LLC
BULLISH
Impact 7/10
Horizonweeks Processed6d 10h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Monitor Q4 2026 for initial SimpleScreen CRC commercial revenue from Abbott's launch and any updates on SimpleScreen Lung adoption. The next catalyst is the multi-cancer detection readout expected in mid-2027.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

FRNM drug pipeline →

SimpleScreen CRC

▲ Bullish Named in this press release
Impact
Phase
Approved
Time to market
Already on the market. The FDA approved SimpleScreen CRC on July 27, 2026. Abbott commercially launched the test in the United States in late September 2026.
Next catalyst
None dated

What to watchSimpleScreen CRC's defining binary (FDA approval) has passed, removing the high-impact binary catalyst. The stock now trades on the commercial execution story via Abbott and on pipeline expansion (lung test). Watch Q4 2026 revenue (due early 2027) for evidence of recurring test-sale volume versus one-time milestones; the next-gen validation data and a potential FDA filing for the updated version are the next potential catalysts to watch for.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$11.56
T+0 close · Nov 10, 2026 · via day close
Latest settled
−8.22%
T+1 · $10.61
Vs SPY
−7.86%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $11.56entry
  2. T+1 · 5d ago −8.22%α −7.86% · $10.61
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Freenome reported Q3 2026 total revenue of $183.5M, far above the $84.9M consensus, driven by a $100M milestone payment from Abbott following FDA approval of SimpleScreen CRC. GAAP net income swung to $60.1M from a loss of $64.5M a year ago. The company guided full-year 2026 revenue to $192M-$194M.

Key Financial Metrics

EPS
$0.58
est −$0.20 · +390.0%
Revenue
$183.5M
est $84.9M · +116.1% · +17628.0% YoY
Rating
beat
Guidance
$192M-$194M
maintained
Free Cash Flow
$35.7M

Key Facts

  • Total revenue $183.5M vs consensus $84.9M, driven by $182.5M in license and collaboration revenue including a $100M milestone from Abbott
  • GAAP net income $60.1M vs net loss of $64.5M in Q3 2025
  • Adjusted EBITDA $117.9M vs negative $56.3M in Q3 2025
  • Cash and marketable securities $430.0M as of September 30, 2026
  • Full-year 2026 revenue guidance $192M-$194M
  • FDA approval of SimpleScreen CRC on July 24, 2026; commercial launch by Abbott on September 30, 2026
  • Subsequent launch of SimpleScreen Lung in October 2026

Financial Impact

Revenue of $183.5M exceeded consensus of $84.9M by 116%; GAAP net income of $60.1M vs consensus loss of $20.0M (implied); cash balance $430M

revenuenet incomecash position

Segment Breakdown

SegmentRevenueGrowth
License and Collaboration$182.5MNot reported
Service and Other$942.0K-9.0%

Risk Factors

  • Revenue heavily dependent on milestone payments; recurring commercial revenue from SimpleScreen CRC is still early stage
  • Full-year 2026 guidance of $192M-$194M implies Q4 revenue of only $2M-$10.5M, suggesting a sharp drop-off after the milestone
  • Operating expenses increased 71% YoY to $113.5M, driven by stock-based compensation and transaction costs

Market Snapshot

Exchange
Nasdaq
Analyst Consensus
91% bullish (11 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3400177

Track record

11 reports on FRNM

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +22.86% at T+20 after the Jul 23, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $10.35 Now $10.09 −2.51% settles Nov 18
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $10.28 Now $10.09 −1.85% settles Nov 17
  3. Nov 10, 20266d ago Press Release Bullish 7/10 Viewing Entry $11.56 to $10.61 Now $10.09 −12.72% ▼ −8.22% −7.86% vs SPY
  4. Oct 29, 202618d ago SC 13G/A Neutral 2/10 Entry $12.86 to $12.48 Now $10.09 −21.54% ▼ −2.95% −1.18% vs SPY
  5. Oct 20, 202627d ago 8-K Bullish 5/10 Entry $14.06 to $14.01 Now $10.09 −28.24% ▼ −0.36% −0.88% vs SPY
  6. Oct 15, 20264w ago Press Release Neutral 1/10 Entry $11.75 to $12.57 Now $10.09 −14.13% ▲ +6.98% +6.56% vs SPY
  7. Aug 28, 202611w ago EFFECT Neutral 4/10 Entry $14.79 to $14.79 Now $10.09 −31.78% · 0.00% +0.30% vs SPY
  8. Aug 18, 202612w ago S-1 Neutral 3/10 Entry $13.63 to $13.51 Now $10.09 −25.97% ▼ −0.88% −0.04% vs SPY
  9. Jul 27, 202616w ago 3 Neutral 2/10 Entry $10.77 to $10.06 Now $10.09 −6.31% ▼ −6.59% −5.05% vs SPY
  10. Jul 23, 202616w ago 8-K Bullish 7/10 Entry $11.24 to $11.38 Now $10.09 −10.23% ▲ +1.25% +1.22% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 7h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026